You just read:

Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

News provided by

Rigel Pharmaceuticals, Inc.

Jun 26, 2018, 07:30 ET